| Citation: |
YANG Ming, FENG Yanlin, LIU Dejun, YU Fengwen, HUANG Kemin, LI Wen, XIAN Weijun, LU Shengnan, WANG Ying. Correlation Between Ki67 Expression and 18F-FDG PET/CT SUVmax in Patient with Diffuse Large B-cell Lymphoma and Their Application in Therapeutic Effect Evaluation[J]. Cancer Research on Prevention and Treatment, 2018, 45(12): 1004-1008. DOI: 10.3971/j.issn.1000-8578.2018.18.0652
|
To discuss the correlation between Ki67 expression and 18F-FDG PET/CT SUVmax in patients with diffuse large B-cell lymphoma(DLBLC) and their application in the evaluation of chemotherapy effect.
We retrospectively analyzed 18F-FDG PET/CT images of 55 patients initially diagnosed as DLBLC in our hospital, observed the correlation between Ki67 expression and SUVmax, evaluated the chemotherapy effect by 18F-FDG PET/CT scan, and analyzed whether age, gender, SUVmax and Ki67 expression were the independent influence factors of chemotherapy effect.
SUVmax was positively correlated with Ki67 expression (P < 0.05), but no correlation with chemotherapy effect (P > 0.05); Age, gender, SUVmax and Ki67 were not independent influencing factors of chemotherapy effect (P > 0.05).
18F-FDG PET/CT SUVmax could predict the proliferation and invasion of DLBCL cells, but there is no correlation between SUVmax and chemotherapy effect. Age, gender, SUVmax and Ki67 expression are not independent influencing factors of chemotherapy effect.
| [1] |
Li XQ, Li GD, GAO ZF, et al. Distribution pattern of lymphoma subtypes in China: A nationwide multicenter study of 10002 cases [J]. J Diagn Concepts Pract, 2012, 11(2): 111-5. http://en.cnki.com.cn/Article_en/CJFDTOTAL-ZDLS201202007.htm
|
| [2] |
Li ZM, Huang JJ, Xia Y, et al. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy[J]. Eur J Haematol, 2012, 88(6): 510-7. doi: 10.1111/ejh.2012.88.issue-6
|
| [3] |
Gaudio F, Giordano A, Perrone T, et al. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab[J]. Acta Haematol, 2011, 126(1): 44-51. doi: 10.1159/000324206
|
| [4] |
李少玲, 付骞千, 张甜甜, 等.原发性胃肠道非霍奇金淋巴瘤的临床特征及预后因素分析[J].肿瘤防治研究, 2017, 44(1): 28-33. doi: 10.3971/j.issn.1000-8578.2017.01.006
Li SL, Fu QQ, Zhang TT, et al. Clinical features and prognostic factors of primary gastrointestinal Non-Hodgkin's lymphoma[J]. Zhong Liu Fang Zhi Yan Jiu, 2017, 44(1): 28-33. doi: 10.3971/j.issn.1000-8578.2017.01.006
|
| [5] |
Meignan M, Gallamini A, Meignan M, et al. Report on tile First International Workshop on Interim-PET-Scan in Lymphoma[J]. Leuk Lymphoma, 2009, 50(8): 1257-60. doi: 10.1080/10428190903040048
|
| [6] |
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma:The Lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059-68. doi: 10.1200/JCO.2013.54.8800
|
| [7] |
Herrmann K, Buck AK, Schuster T, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment[J]. J Nucl Med, 2011, 52(5): 690-6. doi: 10.2967/jnumed.110.084566
|
| [8] |
Xuan CN, WW Lee, Amin AM, et al. Tumor burden assessed by the maximum standardized uptake value and greatest diameter on FDG-PET predicts prognosis in untreated diffuse large-cell lymphoma[J]. Nucl Med Mol Imaging, 2010, 44(1): 39-44. http://www.ncbi.nlm.nih.gov/pubmed/24899936
|
| [9] |
吴红卫, 黄蓉飞, 戴小珍. Ki-67蛋白表达在弥漫大B细胞淋巴瘤预后判断中的意义[J].四川医学, 2014, 35(6): 692-4. http://d.old.wanfangdata.com.cn/Periodical/scyx201406019
Wu HW, Huang RF, Dai XZ. Prognostic Value of Ki-67 Protein Expressions in Patienties with Diffuse Large B-cell Lymphoma[J].Sichuan Yi Xue, 2014, 35(6): 692-4. http://d.old.wanfangdata.com.cn/Periodical/scyx201406019
|
| [10] |
Li ZM, Huang JJ, Xia Y, et al. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy[J]. Eur J Haematol, 2012, 88(6): 510-7. doi: 10.1111/ejh.2012.88.issue-6
|
| [11] |
Yan LX, Liu YH, Luo DL, et al. MYC expression in concert with BCL-2 and BCL-6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma[J]. PLoS One, 2014, 9(8): e104068. doi: 10.1371/journal.pone.0104068
|
| [12] |
Hasselblom S, Ridell B, Sigurdardottir M, et al. Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2008, 49(8): 1501-9. doi: 10.1080/10428190802140055
|
| [13] |
MyLam KJ, El-Galaly TC, Hutchings M, et al. Prognostic impact of Clinician-based interpretation of F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma[J].Leuk Lymphoma, 2014, 55(7): 1563-9. doi: 10.3109/10428194.2013.850165
|
| [14] |
Xie M, Wu K, Liu Y, et al. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a metaanalysis with 702 participants[J]. Med Oncol, 2015, 32(1): 446. doi: 10.1007/s12032-014-0446-1
|
| [15] |
应志涛, 王雪娟, 宋玉琴, 等.弥漫大B细胞淋巴瘤患者规范治疗后行18F-FDG PET/CT检查的预后意义[J].中华血液学杂志, 2012, 33(10): 810-3. doi: 10.3760/cma.j.issn.0253-2727.2012.10.005
Ying ZT, Wang XJ, Song YQ, et al. Prognostic value of 18F-FDG PET/CT after first-line treatment in patients with diffuse large B-cell lymphoma[J]. Zhonghua Xue Ye Xue Za Zhi, 2012, 33(10): 810-3. doi: 10.3760/cma.j.issn.0253-2727.2012.10.005
|
| [16] |
朱璐婷, 岑溪南, 欧晋平, 等.中期18F-FDG PET/CT显像不同评价方法对弥漫大B细胞淋巴瘤患者预后判断价值[J].中国实验血液学杂志, 2017, 25(2): 431-7. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgsyxyxzz201702022
Zhu LT, Cen XN, Ou JP, et al. Values of different evaluation criteria of interim 18f-fdg pet/ct scan for prediction of prognosis in patients with DLBCL[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2017, 25(2): 431-7. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgsyxyxzz201702022
|
| [17] |
Fuertes S, Setoain X, Lopez-Guillermo A, et al. Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2013, 40(4): 496-504. doi: 10.1007/s00259-012-2320-8
|
| [18] |
Barrinton SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the Intemational Conference on Malignant Lymphomas Imaging Working Group[J]. J Clin Oncol, 2014, 32(27): 3048-58. doi: 10.1200/JCO.2013.53.5229
|
| [19] |
张建华, 王荣福, 范岩, 等. 18F-FDG PET/CT评价初诊非霍奇金淋巴瘤代谢活性及其与免疫表型的相关性[J].中华医学杂志, 2014, 94(33): 2576-9. doi: 10.3760/cma.j.issn.0376-2491.2014.33.006
Zhang JH, Wang RF, Fan Y, et al. Metabolic activity measured by 18F-FDG PET/CT in newly diagnosed patients with non-Hodgkin lymphoma: correlation with immunophenotype[J]. Zhonghua Yi Xue Za Zhi, 2014, 94(33): 2576-9. doi: 10.3760/cma.j.issn.0376-2491.2014.33.006
|
| [20] |
梁颖, 吴宁, 方艳, 等.侵袭性淋巴瘤18F标记的氟代脱氧葡萄糖摄取程度与Ki-67表达的相关性[J].中华肿瘤学杂志, 2013, 35(5): 356-60. http://d.old.wanfangdata.com.cn/Periodical/zhzl201305008
Liang Y, Wu N, Fang Y, et al. Correlation of 18F-FDG uptake with tumor-proliferating antigen Ki-67 expression in aggressive lymphoma[J]. Zhonghua Zhong Liu Xue Za Zhi, 2013, 35(5): 356-60. http://d.old.wanfangdata.com.cn/Periodical/zhzl201305008
|
| [21] |
Shou Y, Lu J, Chen T, et al. Correlation of fluorodeoxyglucose uptake and tumor-proliferating antigen Ki67 in lymphomas[J]. J Cancer Res Ther, 2012, 8(1): 96-102. doi: 10.4103/0973-1482.95182
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: